The adoption of healthcare IT leads as the main driver of growth.
The population health management market size is expected to grow by $11.89 billion from 2020 to 2025, according to a market forecast report done by Technavio, a global technology research and advisory company.
Some of the primary growth drivers for the population health management market are the adoption of healthcare IT, increasing number of specialty and multi-chain hospitals, and growing incidence of chronic disorders, according to Technavio. However, factors such as rising cost of installation of population health management platforms may challenge market growth.
Data shared market segmentation highlights in the report were the population health management market being segmented by component into software and services and the software segment has experienced significant market share growth.
In addition, the regional analysis of the report shared the population health management market was segmented into five regions, namely North America, Europe, APAC, MEA, and South America. In those regions, 59% of the growth is expected to originate from North America. Other findings state the U.S. and Canada are the key countries for the population health management market in North America. Lastly, the report indicates that an increasing number of specialty and multi-chain hospitals will drive the population health management market growth in North America during the forecast period.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More